BACKGROUND: In preterm infants, low levels of insulin-like growth factor-I (IGF-I) and IGF binding protein 3 (IGFBP-3) are associated with impaired brain growth and retinopathy of prematurity (ROP). Treatment with IGF-I/IGFBP-3 may be beneficial for brain development and may decrease the prevalence of ROP. METHODS: In a phase II pharmacokinetics and safety study, five infants (three girls) with a median (range) gestational age (GA) of 26 wk + 6 d (26 wk + 0 d to 27 wk + 2 d) and birth weight of 990 (900-1,212) g received continuous intravenous infusion of recombinant human (rh)IGF-I/rhIGFBP-3. Treatment was initiated during the first postnatal day and continued for a median (range) duration of 168 (47-168) h in dosages between 21 and 111 µg/kg/24 h. RESULTS: Treatment with rhIGF-I/rhIGFBP-3 was associated with higher serum IGF-I and IGFBP-3 concentrations (P < 0.001) than model-predicted endogenous levels. Of 74 IGF-I samples measured during study drug infusion, 37 (50%) were within the target range, 4 (5%) were above, and 33 (45%) were below. The predicted dose of rhIGF-I/rhIGFBP-3 required to establish circulating levels of IGF-I within the intrauterine range in a 1,000 g infant was 75-100 µg/kg/24 h. No hypoglycemia or other adverse effects were recorded. CONCLUSION: In this study, continuous intravenous infusion of rhIGF-I/rhIGFBP-3 was effective in increasing serum concentrations of IGF-I and IGFBP-3, and was found to be safe.
BACKGROUND: In preterm infants, low levels of insulin-like growth factor-I (IGF-I) and IGF binding protein 3 (IGFBP-3) are associated with impaired brain growth and retinopathy of prematurity (ROP). Treatment with IGF-I/IGFBP-3 may be beneficial for brain development and may decrease the prevalence of ROP. METHODS: In a phase II pharmacokinetics and safety study, five infants (three girls) with a median (range) gestational age (GA) of 26 wk + 6 d (26 wk + 0 d to 27 wk + 2 d) and birth weight of 990 (900-1,212) g received continuous intravenous infusion of recombinant human (rh)IGF-I/rhIGFBP-3. Treatment was initiated during the first postnatal day and continued for a median (range) duration of 168 (47-168) h in dosages between 21 and 111 µg/kg/24 h. RESULTS: Treatment with rhIGF-I/rhIGFBP-3 was associated with higher serum IGF-I and IGFBP-3 concentrations (P < 0.001) than model-predicted endogenous levels. Of 74 IGF-I samples measured during study drug infusion, 37 (50%) were within the target range, 4 (5%) were above, and 33 (45%) were below. The predicted dose of rhIGF-I/rhIGFBP-3 required to establish circulating levels of IGF-I within the intrauterine range in a 1,000 g infant was 75-100 µg/kg/24 h. No hypoglycemia or other adverse effects were recorded. CONCLUSION: In this study, continuous intravenous infusion of rhIGF-I/rhIGFBP-3 was effective in increasing serum concentrations of IGF-I and IGFBP-3, and was found to be safe.
Authors: D N Herndon; P I Ramzy; M A DebRoy; M Zheng; A A Ferrando; D L Chinkes; J P Barret; R R Wolfe; S E Wolf Journal: Ann Surg Date: 1999-05 Impact factor: 12.969
Authors: Cecilia Camacho-Hübner; Stephen Rose; Michael A Preece; Mark Sleevi; Helen L Storr; Farideh Miraki-Moud; Francesco Minuto; Jan Frystyk; Alan Rogol; Geoffrey Allan; Andreas Sommer; Martin O Savage Journal: J Clin Endocrinol Metab Date: 2006-01-10 Impact factor: 5.958
Authors: Chatarina Lofqvist; Jing Chen; Kip M Connor; Alexandra C H Smith; Christopher M Aderman; Nan Liu; John E Pintar; Thomas Ludwig; Ann Hellstrom; Lois E H Smith Journal: Proc Natl Acad Sci U S A Date: 2007-06-13 Impact factor: 11.205
Authors: Jou-Ku Chung; Boubou Hallberg; Ingrid Hansen-Pupp; Martin A Graham; Gerald Fetterly; Jyoti Sharma; Adina Tocoian; Nerissa C Kreher; Norman Barton; Ann Hellström; David Ley Journal: Pediatr Res Date: 2016-11-21 Impact factor: 3.756
Authors: Ann Hellström; David Ley; Ingrid Hansen-Pupp; Boubou Hallberg; Luca A Ramenghi; Chatarina Löfqvist; Lois E H Smith; Anna-Lena Hård Journal: Growth Horm IGF Res Date: 2016-09-28 Impact factor: 2.372